Improved Outcomes in Colon and Rectal Surgery part 21 pptx

 improved outcomes in colon and rectal surgery more favorable outcomes, Zmora et al. were able to achieve a 53% healing rate in a prospective study of 60 patients with complex cryptoglandular fistulas treated with fibrin glue with intraadhe- sive ceftazidime.(63) The wide variety of successful healing in studies looking at the use of fibrin glue in the treatment of fistula-in-ano is multifactorial. Differences in the trials include patient selection, use of autologous versus commercially prepared fibrin adhesive, etiology of the fistula (cryptoglandular vs. Crohn’s disease vs. other causes), complexity of the fistula, and length of follow-up. While the application of the tissue adhesive seems fairly straightforward, there are also assuredly subtle differences in the application techniques of different surgeons. The heterogeneity of the published trials makes direct com- parisons very difficult. While success rates vary over a wide range, the advantages of attempting to treat high transsphincteric fistulas with fibrin glue in terms of simplicity of technique, negligible complication rate, and ease of reapplication for failed treatments make it an attractive option, at least initially. Most surgeons seem willing to accept a higher than expected failure rate in exchange for a low complication rate, understanding that treatment failures will need to be addressed in some other manner. Anal Fistula Plug The topic that has perhaps generated the most discussion in recent years is the use of the Surgisis® Anal Fistula Plug™ (AFP) (Cook Surgical, Inc., Bloomington, IN). The AFP is a cone shaped bioprosthetic fashioned from Surgisis®, a bioabsorbable xenograft made of lyophilized porcine intestinal submucosal. Surgisis® has been used extensively in abdominal and inguinal hernia repairs. (64–66) It is relatively resistant to infection, produces no foreign body or giant cell reaction, and becomes repopulated with host cell tissue within 3–6 months, providing mechanical integrity while acting as a scaffold to guide tissue incorporation. The AFP is inserted into the fistula tract and secured at the level of the primary opening. The principal effect is to close the primary fistula opening, though incorporation of the AFP into the tract itself can theoretically contribute to fistula closure. The advantages of this technique include negligible risk of incontinence postoperatively, relative simplicity in placement of the AFP, less postoperative patient discomfort, and the ability to repeat the procedure in cases of failure without major consequences. Johnson et al. (67) initially reported a small, nonrandomized, prospective cohort study comparing the efficacy of fibrin glue versus AFP in the treatment of high transsphincteric fistulas. At a mean follow-up of 14 weeks, in the fibrin glue cohort, healing was seen in 40% (4 of 10), whereas in the AFP cohort, 13 of 15 (87%) had healed (p < 0.05). The main advantage of the plug technique compared with fibrin glue was felt to be the ability to securely close the primary opening, which is felt to be a critical step in the successful treatment of anal fistulas. The drawback of fibrin glue is its liquid nature, and its tendency to run out of the fistula tract, even when both primary and secondary openings are sutured closed. Champagne et al. (68) went on to report an overall healing rate of 83% for cryptoglandular fistulas treated with an AFP in a series of 46 patients followed for a mean of 12 months (range 6–24 months). The same authors reported a similar 80% success rate for treatment of Crohn’s-related fistulas with an AFP in 20 patients at a median follow-up of 10 months.(69) Ellis (70) also reported success in a small group patients with transsphincteric (n = 13) and rectovaginal fistulas (n = 5) with 88% complete fistula closure at a median follow-up of 6 months. Other studies report inconsistent results. Van Koperen et al. reported a series of 17 patients treated with an AFP with only 41% success.(71) Patients with cryptoglandular disease and no history of previous fistula surgery fared better than those with a history of previous surgical intervention. In the small subsets of patients with Crohn’s disease (n = 1) and HIV infection (n = 2), 100% healing was seen, as opposed to 29% complete healing (4 of 14) in patients with cryptoglandular disease. Schwandner et al. (72) reported an overall success rate of 61%. The subset of patients with Crohn’s fistulas related to Crohn’s disease showed higher closure rates than those with fistulas of cryptoglandular origin (85.7% vs. 45.5%). More recent studies have varied widely in their results, reporting healing rates ranging from 24% to 71.4%.(73–76) One of the largest prospective studies was reported by Ky et al. (77) The authors studied 45 patients with simple (n = 24) and complex (n = 20) anorectal fistulas treated with AFP’s. An early healing rate of 84% at 3 to 8 weeks postoperatively progressively declined to 54.6% at a mean follow-up of 6.5 months. Healing rates were significantly higher in patients with simple rather than complex fistulas (70.8% vs. 35%, p < 0.02) and in patients without Crohn’s disease compared to those with Crohn’s disease (66.7% vs. 26.6%, p < 0.02). Despite a number of publications attesting to the safety and efficacy of the AFP, uniformity of opinion was lacking because of contradictory reports in the literature as well as a lack of Level I evidence showing any clear benefit. Because of this, a consensus conference involving 15 surgeons with extensive experience with the AFP was held in May 2007 to make formal recommendations regarding inclusion/exclusion criteria, pre-, intra-, and postoperative management, and definition of outcome failure.(78) Some technical notes regarding placement of the plug bear men- tioning. It is essential that all sources of perineal sepsis are resolved prior to placement. The use of pre- or postoperative antibiotics and preoperative bowel cleansing has not been studied in a prospective, randomized fashion. In most of the studies described herein, a preoperative dose of intravenous antibiotic was administered, and varying regimens of postoperative antibiotics were utilized. The consensus panel did not make specific recommendations regarding preoperative bowel preparation; a single dose of preoperative systemic antibiotics was recommended without postoperative continuation.(78) Thorough cleansing of the fistula tract with hydrogen peroxide is generally recommended. Mechanical cleansing via curetting, debridement, or brushing is not recommended due to disruption and enlargement of the tract. The technique of fixation of the plug to the primary opening recommended by the manufacturer involves a figure of eight absorbable suture through the mucosa, submucosa, and internal anal sphincter that inverts the proximal end of the anal fistula plug beneath the mucosa, anchor- ing it to the tract while closing the primary opening over the plug (Figure 19.5). Earlier studies as well as the manufacturer’s recommendations suggested fixation of the distal end of the plug to the secondary fistula opening as an essential step in plug placement. Most surgeons have abandoned this step, now simply trimming the 9 surgery and nonoperative therapy of perirectal abscesses and anal fistulas distal end of the plug flush with the skin without fixation, as it has been suggested that external fixation creates tension on the primary fixation site with patient movement, predisposing to plug extrusion. The consensus panel also recommended not fixing the distal end of the plug to the secondary opening. The majority of AFP failures are due to plug extrusion, untreated or persistent source(s) of perineal sepsis, or postoperative infectious complications. Ligation of Intersphincteric Fistula Tract An interesting new concept in the surgical management of fistula- in-ano has recently been described—ligation of the intersphincteric fistula tract (LIFT).(79) In this method, intersphincteric dissec- tion is performed and the fistula tract is identified and ligated in this plane, leaving the sphincter muscles themselves undisturbed. The authors reported complete fistula healing in 17 of 18 patients (94.4%), with a mean healing time of 4 weeks and no disturbances in anal function. While this study was small and observational in nature, the simplicity of the technique and its negligible impact on sphincter function certainly warrant further investigation. ADDITIONAL ISSUES Recurrence Recurrence after incision and drainage of an anorectal abscess and anal fistula, should be considered as two entities. True recurrence after abscess drainage is typically due to inadequate drainage or inadequate postoperative care. What is more commonly seen is actually “persistent” disease as the abscess cavity matures into a fistula. Vasilevsky and Gordon reported recurrent or persistent disease in 48% of patients (11% recurrent abscess, 37% fistula-in-ano) after undergoing incision and drainage of anorectal abscesses.(80) Results similar to these have been reported by several authors, which argue against primary fistulotomy at the time of initial abscess drainage, as unnecessary fistulotomy Figure 19.5 AFP product insert. (A) (C) (D)(B) 9 improved outcomes in colon and rectal surgery with potential altered fecal continence can be avoided in approximately 50% of patients. Common reasons for recurrent anorectal infection include missed infection at the time of initial drainage in adjacent anatomic planes, presence of an undiagnosed fistula at the time of initial abscess drainage, and failure to completely drain the abscess initially.(81) In a series of 500 patients undergoing anorectal abscess drainage, Onaca et al. reported that 7.6% required reoperation within 10 days of the initial procedure.(82) Factors leading to reoperation included incomplete drainage (23%), missed loculations (15%), missed abscesses (4%), and postoperative bleeding (3%). Horseshoe abscesses were associated with a 50% rate of operative failure.(82) Similarly, recurrent fistula-in-ano is often seen after surgical management due to a failure to identify a primary opening or recognize secondary extensions of a fistula. Secondary tracts accounted for early recurrences in 20% of patients studied by Sangwan. (83) Sygut et al. reported a 14.3% recurrence rate after surgical management of fistula-in-ano, though recurrence was much more common after surgery for recurrent fistulas (51.7%) than primary fistulas (5.4%).(84) In this same study, recurrence was also more common in multi-tract fistulas (32.4%) than single-tract fistulas (12%). Recurrence rates after fistulotomy range from 0–18% (Table 19.1). Premature closure of the fistulotomy wound is a clear risk factor for recurrence; this can be prevented by creating an external wound larger than the anal wound, ensuring that the internal wound will heal first. Meticulous postoperative care is essential to avoid bridging and pocketing of the wound.(99, 100) Epithelialization of the tract may also occur, leading to persistent fistula-in-ano.(101) Garcia-Aguilar et al. performed a retrospective study that reviewed the records of 624 patients undergoing surgery for fistula-in-ano in an effort to determine factors associated with recurrence and incontinence.(98) Recurrence was seen in 8% of patients; univariate and multivariate regression analysis showed that factors associated with recurrence included complex fistula type, horseshoe extension, lack of identi- fication, or lateral location of the primary fistula opening, previous fistula surgery, and the experience of the surgeon. Recurrence rates after staged fistula repairs using setons range from 0% to 9% (34, 98, 102–109), though the largest study with a 0% recurrence rate had only 21 patients.(106) Interestingly, the success rate of fistula surgery has been shown to decrease with time. In a study by van der Hagen et al. (110), recurrence rates following fistulotomy at 12, 48, and 72 months were 7%, 26%, and 39%, respectively, with 33% of recurrences occurring in the first 24 months after surgery. A similar trend was seen following the use of endorectal advancement flaps, with recurrence rates of 22%, 63%, and 63% seen at 12, 48, and 72 months respectively; 69% of recurrences were seen within the first 24 months. Van Koperen et al. (111) demonstrated recurrence rates at 3-year follow-up of 7% for fistulotomy, and 21% for rectal advancement flaps. Mizrahi et al. (112) described features associated with fistula recurrence in a series of 106 consecutive endorectal advancement flaps performed on 94 patients. Recurrence was seen in 40.4% of patients at a mean follow-up of 40.3 months. Recurrence was not associated with prior attempt at repair, type of fistula, origin of fistula, preoperative steroid use, postoperative bowel con- finement, postoperative antibiotic use, or creation of a diverting stoma. Recurrence was significantly more common in patients with Crohn’s disease (p < 0.04). Sonada et al. reported a similar recurrence rate of 36.4% of patients undergoing endorectal advancement flap for repair of anorectal and rectovaginal fistulas in a series of 105 patients.(42) Factors that negatively impacted the healing rate were Crohn’s disease (p = 0.027) and a diagnosis of rectovaginal as opposed to anorectal fistula (0.002). Patients on oral corticosteroid therapy showed a trend towards recurrence, though this did not reach statistical significance; no patients taking more than 20 mg/day of prednisone achieved long-term healing. Cigarette smoking has been shown to negatively impact fistula closure after endorectal advancement flap. In a series of 105 patients undergoing endorectal advancement flap for anal fistulas not related to Crohn’s disease, Zimmerman et al. reported successful fistula closure in 69%.(113) In patients who did not smoke cigarettes, healing was seen in 79%, compared with 60% in smokers (p < 0.037). Furthermore, a significant correlation was seen between the healing rate and the number of cigarettes smoked per day (p = 0.003). Using intraoperative laser Doppler flowmetry, it has also been shown that median bloodflow before endorectal advancement flap in nonsmokers was 35 volts, compared with 18 volts in smokers (p = 0.018).(114) Thus, it seems likely that impaired wound healing due to diminished perfusion may be a contributing factor in the failure of endorectal advancement flaps in smokers. Efforts to encourage smoking cessation preoperatively should be undertaken to minimize postoperative morbidity. Incontinence Fecal incontinence after abscess drainage should be relatively infrequent and is typically the result of iatrogenic damage to the sphincter mechanism. Compromised continence may also be seen postoperatively if the external sphincter is damaged during incision and drainage in patient with borderline preoperative continence. Inadvertent injury to the puborectalis during drainage of supralevator abscesses has also been reported.(115) Prolonged packing may prevent granulation tissue formation and promote generation of excessive scar tissue.(116) Primary fistulectomy at the time of incision and drainage has also been reported to cause disturbed fecal continence.(33) On the other hand, incontinence rates following surgical management of fistula-in-ano vary widely. The incidence of incontinence is related to the complexity of the fistula and the level of the primary fistula opening, with complex fistulas and those with posterior and high openings and fistula extensions at a higher risk.(97) Posterior fistulotomy has a higher incidence of recurrence due to a more circuitous route of the tract, resulting in division of more sphincter muscle. Drainage of extensions may damage small nerves and create scar tissue around the anorectum.(97) The incidence of incontinence is also related to the patient’s preoperative sphincter function and their would-healing ability. The incidence of impaired continence also increases with age and is more common in females.(98) Fecal seepage without true sphincter compromise can occur if the edges of a fistulotomy wound do not heal completely, preventing complete closure of the anus and allowing for leakage of fecal contents, and flatus. 9 surgery and nonoperative therapy of perirectal abscesses and anal fistulas In a large review of 844 patients undergoing surgery for anal fistulas, Rosa et al. (117) demonstrated a 6.9% incidence of altered postoperative sphincter function. Incontinence to flatus was seen in 4.0%, liquid stool in 2.6%, and solid fecal material in 0.3%. The majority of patients in this series underwent fistulotomy or a combined fistulotomy-fistulectomy method. Sygut et al. reported postoperative gas and/or stool incontinence in 10.7% of patients undergoing surgical management of anal fistulas, mainly in the form of fistulotomy and cutting setons.(84) In this study, rates of incontinence were higher following surgery for recurrent vs. primary fistulas (39.7% vs. 3.7%) and after surgery for multitract as opposed to singletract fistulas (29.4% vs. 8.3%). In a review of 624 patients undergoing anal fistula surgery, Garcia-Aguilar et al. (98) showed that 45% of patients complained of some degree of altered continence. Factors associated with postoperative incontinence included female sex, high fistula type, type of surgery, and previous fistula surgery. Incontinence after staged fistulotomy using a seton ranges from 0% to 64%.(34, 97, 98, 102–109) Again, all of the studies showing no recurrences were small, with the largest being only 20 patients.(105) In a study looking at long-term functional outcome, Van Koperen et al. (111) reported that after fistulotomy for low cryptoglandular fistulas, fecal soiling was seen in 41% of patients and fecal incontinence was seen in 2.8% of patients at 3 year follow-up. Following rectal advancement flaps, soiling was seen in 43% and incontinence was seen in 2.9% at 3 year follow-up. None of potential risk factors examined (sex, age, prior fistula surgery, smoking) were significant in both univariate and multivariate analysis. Schouten et al. (39) showed that 35% of patients had deteriorated continence postoperatively after endorectal advancement flap. The number of previous attempts at fistula repair did not adversely affect continence. Zimmerman et al. (46) reported deteriorated continence after anocutaneous advancement flap in 30% of patients. Aguilar et al. reported disturbances in continence to flatus in 7% and liquid stool in 6% in a series of 189 patients undergoing fistulectomy with endorectal advancement flap.(118) Kodner et al. reported unchanged or improved continence in 98% of patients undergoing endorectal advancement flap for anorectal fistulas.(40) Other series have reported no alteration in postoperative continence after rectal advancement flaps.(45, 119) Toyonaga et al. performed an interesting study looking at pre- and postfistulotomy manometry studies.(120) They found that fistulotomy significantly decreased maximum resting pressure (85.9 to 60.2 mmHg, p < 0.0001) and length of the high pressure zone (3.92 to 3.82 cm, p = 0.035), but did not affect voluntary contraction pressure (164.7 to 160.3 mmHg, p = 0.2792). Anal sphincter dysfunction, in the form of soiling, incontinence to flatus, or incontinence to liquid stool, occurred in 20.3% of patients. Multivariate analysis showed that while fistulotomy did not affect voluntary contraction pressure, those with lower preoperative voluntary contraction pressures were more likely to suffer from altered continence postoperatively, as were those who had under- gone multiple drainage procedures. Age, sex, previous fistula surgery, duration of symptoms, and location and level of the primary opening did not significantly influence continence postoperatively. The authors concluded that preoperative anal manometry may be helpful in choosing the proper surgical procedure for patients with fistula-in-ano. Manometry studies following endorectal advancement flaps performed by Uribe et al. (121) also showed significant reduction in maximum resting pressure 3 months after surgery (83.6 vs. 45.6 mmHg, p < 0.001), as well as significant reduction in maximum squeeze pressure (208.8 vs. 169.5 mmHg, p < 0.001). Disturbed anal continence was seen 21.4% of patients. None of the variables looked at (age, sex, previous fistula surgery, Crohn’s disease) were predictive of postoperative incontinence. In contrast, manometry studies following endorectal advancement Table 19.1 Results of fistula surgery. Author Year No. Patients Recurrence % Incontinence % Bennett (85) 1962 108 2.0 36.0 Hill (86) 1967 626 1.0 4.0 Lilius (87) 1968 150 5.5 13.5 Mazier (88) 1971 1000 3.9 0.001 Ani & Solanke (89) 1976 82 17.0 1.0 Marks & Ritchie (90) 1977 793 – 3, 17, 25* Ewerth et al. (91) 1978 143 2.8 3.5 Adams & Kovalcik (92) 1981 133 3.8 0.8 Kuijpers (93) 1982 51 4.0 10.0 Sainio & Husa (94) 1985 199 11.0 34.0 Vasilevsky & Gordon (95) 1985 160 6.3 0.7, 2.0, 3.3** Fucini (96) 1991 99 3.0 0, 0.2, 0.5*** Van Tets (97) 1994 19 – 33.0 Sangwan (83) 1994 461 6.5 2.8 Garcia-Aguilar et al. (98) 1996 293 7.0 42.0 * 3% solid stool, 17% liquid stool, 25% flatus. ** 0.7% solid stool, 2.0% liquid stool, 3.3% flatus. *** 0 solid stool, 0.2% liquid stool, 0.5% flatus. 9 improved outcomes in colon and rectal surgery flaps were performed by Kreis et al. (122), showing no difference in preoperative and postoperative maximum squeeze pressure (100.0 vs. 118.0 mmHg), maximum resting pressure (56.6 vs. 52.8 mmHg), rectal compliance (4.4 vs. 3.5 ml/mmHg), or any other anorectal manometry parameter. Other studies evaluating preoperative manometric parameters differ somewhat. Chan and Lin (123) examined 45 patients with intersphincteric fistulas and showed low preoperative resting pressure to be the only independent factor predicting postoperative incontinence. In a prospective study by Perez et al. (124) looking at combined fistulotomy with primary sphincter reconstruction, there were significant preoperative differences seen on manometry between continent and incontinent patients that disappeared after operation. There were neither clinical nor manometric differences between pre- and postoperative values in fully continent patients, although three patients (12.5%) reported minor altera- tions of continence. Crohn’s Disease The overall incidence of anorectal fistulas associated with Crohn’s disease limited to the ileocecum is 20–25%; this rises to approximately 60% when Crohn’s disease affects the rectum.(125) Disease isolated to the anorectum is seen in only 5% of patients.(126) Fistulizing anorectal Crohn’s disease can be among the most frustrating con- ditions surgeons are called upon to manage. Surgical treatment is fraught with the problems of poor wound healing, delayed wound healing, and sphincter injury. It is widely held that incontinence in patients with anorectal Crohn’s disease is usually the result of aggressive surgeons and not aggressive disease.(127) Thus, a conservative approach is practiced in most instances, taking extreme care to pro- tect the sphincter. When in doubt, one cannot be faulted for simply draining the suppurative process by placing a draining seton. Any acute infectious process must be drained appropriately and medical management of the disease should be optimized before even considering surgical treatment. For low-lying posterior fistulas, fistulotomy may be considered, especially if there is not rectal disease. Anterior fistulotomies in females should be avoided because of the risk of postoperative incontinence. Endorectal advancement flaps are also a viable option, especially when there is no rectal disease. Joo et al. (128) described 31 endorectal advancement flaps performed in 26 patients, resulting in fistula eradication in 71% of cases. Success was more likely in the absence of concomitant small bowel Crohn’s disease than in patients with concomitant small bowel Crohn’s disease (87% vs. 25%, p < 0.05). Other series have shown that the presence of Crohn’s disease predisposes endorectal advancement flaps to failure.(42, 112) Data regarding the efficacy of the Surgisis© AFP is mixed. As mentioned earlier, O’Connor et al. reported the AFP to be effective in 80% of patients and 83% of fistula tracts in a series of 20 patients with 36 fistula tracts. Patients with single fistulas were more likely to have success and success was not correlated with antitumor necrosis factor therapy.(69) Schwander et al. actually showed better healing rates with AFP’s in patients with anal fistulas and Crohn’s disease than in patients without Crohn’s (85.7% vs. 45.5%). On the other hand, Ky et al. (77) reported complete fistula healing with an AFP in 26.6% of patients with Crohn’s disease compared to 66.7% of patients without Crohn’s (p < 0.02). For patients with fulminant perineal sepsis due to fistulizing perineal Crohn’s, a low threshold for a diverting stoma must be entertained, especially since a large number of these patients will go on to require proctectomy. Nonsurgical Management For the most part, there is no role for nonoperative management of anorectal abscesses. Occasionally, an early inflammatory process, marked by pain and erythema or induration without fluc- tuance, may be prevented from progressing to an abscess with early initiation of antibiotic therapy. However, once an abscess has formed, antibiotics alone are insufficient. Failure to appropriately drain an anorectal abscess in a timely manner subjects the patient to the risk of progressive perineal sepsis, including operative risks associated with surgery in the septic patient, technical complications associated with anorectal surgery in the face of severe inflammation (unclear anatomy, bleeding, risk of inadvertent sphincter injury), and necrotizing perineal soft tissue infection (Fournier’s gangrene) with associated mortality rates as high as 67% (129–132), as described below. Nonoperative management of anal fistulas falls into two main categories – those related to cryptoglandular disease and those related to Crohn’s disease. There is very little in the literature regarding nonoperative management of chronic cryptoglandular fistulas. Obviously, acute suppurative processes must be drained, typically with a seton. Draining setons may be left in place indef- initely, with little consequence other than patient discomfort. As discussed later, in exceedingly rare cases, invasive carcinoma may develop in the setting of a chronic fistula. Conservative (nonoperative) therapy for anal fistulas in the setting of Crohn’s disease is the standard approach typically followed. (331) Initial drainage of the acute suppurative process without division of the fistula tract is typically performed by placing draining setons. Long-term indwelling draining setons may be used as an effective management modality for complex perianal Crohn’s fistulas, without a negative impact on continence.(134) A number of medical therapies are utilized for the treatment of anal fistulas related to Crohn’s disease. Ciprofloxacin has been reported to improve symptoms in two small, uncontrolled trials. (135, 136) Metronidazole had also been studied in a number of uncontrolled trials with varying rates of symptom relief and fistula healing.(137–140) Metronidazole must be used for maintenance to be effective, as high recurrence rates are seen on discontinuation.(133) The combination of ciprofloxacin and metronidazole has also been shown to be effective in a small retrospective study at reducing symptoms and healing fistulas; most patients in this series also regressed with cessation of treatment.(141) A number of immunomodulators are also employed in the medical management of perianal Crohn’s fistulas. Azathioprine and 6-mercaptopurine have been shown to induce complete fistula closure in 31–39% of patients, with even higher rates of symptom reduction without complete closure.(142–144) Again, recurrence occurred frequently with discontinuation of treatment. Methotrexate and cyclosporine A have each been shown to be efficacious in inducing remission on patients with Crohn’s disease (145, 146), though data regarding their effect specifically on anal fistulas resulting from Crohn’s disease has been lacking. 9 surgery and nonoperative therapy of perirectal abscesses and anal fistulas Infliximab, a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α), has revolutionized the medical management of Crohn’s disease. In mucosal biopsies of patients with Crohn’s disease, enhanced secretion of TNF-α with failure to release enhanced quantities of soluble TNF-α receptors is seen. Infliximab reduces disease activity by blocking the effects of TNF-α and has been shown to be an effective maintenance therapy in patients with Crohn’s disease with fistulas (147) and without fistulas.(148) Despite a lack of convincing Level 1 data proving the efficacy of infliximab specifically in the setting of perianal Crohn’s fistulas, its use in this setting is becoming more widespread. Long-term data regarding the efficacy of infliximab in effect- ing perianal fistula closure is lacking. The combination of seton drainage and infliximab infusion has been shown to be effective as well, with healing rates ranging from 47–100%.(149–151) The timing of seton removal in these patients is not clear. If removed too early, the patient is at risk of developing recurrent perianal abscesses, and if they are not removed, complete fistula healing will not occur. Poritz et al. (152) reported 44% complete anal fistula healing when the seton(s) were removed between the second and third infliximab infusions. As the use of infliximab escalates, patients who have failed treatment are undergoing subsequent surgical intervention for anorectal fistulas, raising concerns over whether preoperative infliximab treatment has an adverse effect on anal fistula surgery. Gaertner et al. (153) showed that patients with Crohn’s disease and anal fistulas who were treated initially with infliximab and underwent subsequent surgical treatment showed similar healing rates compared with patients who did not undergo previous infliximab treatment (60% vs. 59%). Kraemer et al. (154) reported that 9 of 11 patients with Crohn’s disease and anal fistulas who underwent preoperative infliximab treatment followed by advancement flaps demonstrated complete healing. Thus, it seems feasible to proceed with anal fistula surgery after failed infliximab treatment, expect- ing to acceptable rates of wound healing. HIV-positive patients Patients with anorectal abscesses who are HIV-positive require timely incision and drainage, as presentation is often delayed. In this population, the use of adjunct antibiotics is strongly recommended. Because these patients are at increased risk if of poor wound healing (155), care should be taken to minimize the size of surgical wounds while ensuring adequate drainage. In one study (155), serious septic complications or uncommon pre- sentations of anorectal sepsis were seen in 13% of HIV-positive patients who initially presented with anorectal suppuration. In another study (156), perianal sepsis in HIV-positive patients was frequently associated with in situ neoplasia. Interestingly, immunosuppressive disease has not been found to contribute to the need for early reoperation following initial abscess drainage.(82) In a review by Munoz-Villasmil et al. (157) of 83 immunocom- promised patients with perianal sepsis, 28% were HIV-positive. In this population, 91% of surgical wounds were healed in 8 weeks. Incontinence was seen in 6% of patients postoperatively, and recurrence was seen in 7%. Carcinoma Associated with Fistula-In-Ano In rare instances, patients with long-standing anal fistulas may go on to develop invasive carcinoma. Although this occurs more commonly in the setting of Crohn’s disease, carcinomas arising from anal fistulas have been reported in patients without Crohn’s disease.(158, 159) While Crohn’s disease is associated overall with an approximately 6-fold increase in colorectal cancer compared to the general population (160), the incidence of anal cancer arising from an anal fistula in the setting a Crohn’s disease is significantly lower. In a series of over 1000 patients with anorectal manifestations of Crohn’s disease, Ky et al. (125) reported seven patients (0.7%) who developed invasive carcinoma related to anorectal fistulas. Four patients developed squamous cell carcinoma and three developed adenocarcinoma. The average duration of Crohn’s disease before cancer diagnosis was 14 years and average age at diagnosis was 47 years. Presenting symptoms included pain (n = 5), persistent fistula (n = 2), persistent anal ulcer (n = 1), and rectovaginal fistula (n = 1). In four patients, the diagnosis of carcinoma was overlooked at initial examination, resulting in significant delay in diagnosis. All four patients with squamous cell carcinoma were treated with chemoradiation. Two of these were successfully treated with no evidence of residual disease. One died of carcinoma 6 months after treatment. The fourth patient required abdominoperineal resection due to persistent disease and died 1.5 years later. One of the patients treated successfully with chemoradiation developed a second primary squamous cell carcinoma 11 years later, which was successfully treated with wide local exci- sion. All three patients with adenocarcinoma were treated with abdominoperineal resection. One received preoperative chemoradiation; this patient died 3.5 years later. Of the remaining 2 patients, one died in the early postoperative period, and the second died of unrelated causes 5 years later. A number of other case reports in the literature describe patients with carcinoma arising from chronic fistulas and unhealed wounds in a setting of Crohn’s disease.(161, 162) The take home message is that one must maintain a high degree of suspicion for carcinoma in patients with persistent or complex anal fistulas, especially in the setting of long-standing Crohn’s disease. In this setting, complex fistulas with associated anorectal strictures and/or severe anorectal pain mandate a thorough examination. In cases where anorectal examination is limited or unequivocal, exam under anesthesia with biopsy or curettage of the fistula tract is essential. Because lesions are typically diagnosed at a later stage of disease, prognosis is poor. Timely diagnosis and institution of appropriate therapy is essential to improve survival rates. REFERENCES 1. Parks AG. Pathogenesis and treatment of fistula-in-ano. Br Med J 1961; 1: 463–9. 2. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63: 1–12. 3. Cirocco WC, Reilly JC. Challenging the predictive accuracy of Goodsall’s rule for anal fistulas. Dis Colon Rectum 1992; 35: 537–42. 4. Halligan S, Stoker J. Imaging of fistula in ano. Radiology 2006; 239: 18–33. 9 improved outcomes in colon and rectal surgery 5. Berman L, IsraelGM, McCarthy SM et al. Utility of magnetic resonance imaging in anorectal disease. World J Gastroenterol 2007; 13: 3153–8. 6. Kuijpers HC, Schulpen T. Fistulography for fistula-in-ano: is it useful? Dis Colon Rectum 1985; 28: 103–4. 7. Weisman RI, Orsay CP, Pearl RK, Abcarian H. The role of fistulography in fistula-in-ano. Report of five cases. Dis Colon Rectum 1991; 34: 181–4. 8. Law PJ, Talbot RW, Bartram CI, Northover JMA. Anal endosonography in the evaluation of perianal sepsis and fistula-in- ano. Br J Surg 1989; 76: 752–2. 9. Cataldo PA, Senagore A, Lutchtefeld MA. Intrarectal ultrasound in the evaluation of perirectal abscesses. Dis Colon Rectum 1993; 36: 554–8. 10. Lengyel AJ, Hurst NG, Williams JG. Pre-operative assessment of anal fistulas using endoanal ultrasound. Colorectal Dis 2002; 4: 436–40. 11. Seow-Choen F, Burnett S, Bartram CI, Nicholls RJ. Comparison between anal endosonography and digital examination in the evaluation of anal fistulas. Br J Surg 1991; 78: 445–7. 12. Cheong DMO, Nogueras JJ, Wexner SD, Jagelman DG. Anal endosonography for recurrent anal fistulas: image enhancement with hydrogen peroxide. Dis Colon Rectum 1993; 36: 1158–60. 13. Poen AC, Felt-Bersma RJ, Eijsbouts QA et al. Hydrogen peroxide-enhanced transanal ultrasound in the assessment of fistula-in-ano. Dis Colon Rectum 1998; 41: 1147–52. 14. Moscowitz I, Baig MK, Nogueras JJ et al. Accuracy of hydrogen peroxide enhanced endoanal ultrasonography in assessment of the internal opening of an anal fistula complex. Tech Coloproctol 2003; 7: 133–7. 15. Navarro-Luna A, Garcia-Domingo MI, Rius-Macias J, Marco-Molina C. Ultrasound study of anal fistulas with hydrogen peroxide enhancement. Dis Colon Rectum 2004; 47: 108–14. 16. Buchanan GN, Bartram CI, Williams AB et al. Value of hydrogen peroxide enhancement of three-dimensional endoanal ultrasound in fistula-in-ano. Dis Colon Rectum 2005; 48: 141–7. 17. Gravante G, Giordano P. The role of three-dimensional endoluminal ultrasound imaging in the evaluation of anorectal diseases: a review. Surg Endosc 2008; 22: 1570–8. 18. Giordano P, Grondona P, Hetzer H et al. Three-dimensional endoanal ultrasonography is better than conventional anal endosonography in the assessment of fistula in ano. Dis Colon Rectum 2004; 47: 607–8. 19. Ratto C, Grillo E, Parello A et al. Endoanal ultrasound- guided surgery for anal fistula. Endoscopy 2005; 37: 722–8. 20. West RL, Dwarkasing S, Felt-Bersma RJ et al. Hydrogen peroxide-enhanced three-dimensional endoanal ultrasonography and endoanal magnetic resonance imaging in evaluating perianal fistulas: agreement and patient preference. Eur J Gastroenterol Hepatol 2004; 16: 1319–24. 21. West RL, Zimmerman DD, Dwarkasing S et al. Prospective comparison of hydrogen peroxide-enhanced three-dimensional endoanal ultrasonography and endoanal magnetic resonance imaging of perianal fistulas. Dis Colon Rectum 2003; 46: 1407–15. 22. Buchanan GN, Halligan S, Bartram CI et al. Clinical examination, endosonography, and MR imaging in preoperative assessment of fistula in ano: comparison with outcome-based reference standard. Radiology 2004; 233: 674–81. 23. Barker PG, Lunniss PJ, Armstrong P et al. Magnetic resonance imaging of fistula-in-ano: technique, interpretation, and accuracy. Clin Radiol 1994; 49: 7–13. 24. Beckingham IJ, Spencer JA, Ward J et al. Prospective evaluation of dynamic contrast enhanced magnetic resonance imaging in the evaluation of fistula in ano. Br J Surg 1996; 83: 1396–8. 25. Beets-Tan RG, Beets GL, van der Hoop AG et al. Preoperative MR imaging of anal fistulas: Does it really help the surgeon? Radiology 2001; 218: 75–84. 26. Schaefer O, Lohrmann C, Langer M. Assessment of anal fistulas with high-resolution subtraction MR-fistulography: comparison with surgical findings. J Magn Reson Imaging 2004; 19: 91–8. 27. Beck DE, Fazio VW, Lavery IC et al. Catheter drainage of ischiorectal abscesses. South Med J 1988; 81: 444–6. 28. Hanley PH, Ray JE, Pennington EE, Grablowsky OM. A ten year follow up study of horseshoe-abscess fistula-in-ano. Dis Colon Rectum 1976; 19: 507–15. 29. Rosen SA, Colquhoun P, Efron J et al. Horseshoe abscesses and fistulas: how are we doing? Surg Innov 2006; 13: 17–21. 30. Vasilevsky C. Fistula-in-ano and abscess. In: Beck DE, Wexner SD, eds. Fundamentals of Anorectal Surgery, 2nd Edition. Philadelphia: W.B. Saunders, 1998: 153–73. 31. Fucini C. One stage treatment of anal abscesses and fistulas. A clinical appraisal on the basis of two different classifica- tions. Int J Colorectal Dis 1991; 6: 12–6. 32. Tang C-L, Chew S-P, Seow-Choen F. Prospective randomized trial of drainage alone vs drainage and fistulotomy for acute perianal abscesses with proven internal opening. Dis Colon Rectum 1996; 39: 1415–17. 33. Schouten WR, van Vroonhoven TMJV. Treatment of anorectal abscesses with or without primary fistulectomy: results of a prospective randomized trial. Dis Colon Rectum 1991; 34: 60–3. 34. Pearl RK, Andrews JR, Orsay CP et al. Role of the seton in the management of anorectal fistulas. Dis Colon Rectum 1993; 36: 573–9. 35. Parks AG, Stitz RW. The treatment of high fistula-in-ano. Dis Colon Rectum 1976; 19: 487–99. 36. Kennedy HL, Zegarra JP. Fistulotomy without external sphincter division for high anal fistulae. Br J Surg 1990; 77: 898–90. 37. Fazio VW. Complex anal fistulae. Gastroenterol Clin North Amer 1987; 16: 93–114. 38. Gordon PH. Management of anorectal abscess and fistulous disease. In Kodner IJ, Fry RD, Roe JP, eds. Colon, Rectal and Anal Surgery. St. Louis: CV Mosby, 1985: 91–107. 39. Schouten WR, Zimmerman DD, Briel JW. Transanal advancement flap repair of transsphincteric fistulas. Dis Colon Rectum 1999; 42: 1419–22. 9 surgery and nonoperative therapy of perirectal abscesses and anal fistulas 40. Kodner IJ, Mazor A, Shemesh EI et al. Endorectal advancement flap repair of rectovaginal and other complicated anorectal fistulas. Surgery 1993; 114: 682–9. 41. Dixon M, Root J, Grant S, Stamos MJ. Endorectal flap advancement repair is an effective treatment for selected patients with anorectal fistulas. Am Surg 2004; 70: 925–7. 42. Sonada T, Hull T, Piedmonte MR, Fazio VW. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum 2002; 45: 1622–8. 43. Hyman N. Endoanal advancement flap repair for complex anorectal fistulas. Am J Surg 1999; 178: 337–40. 44. Chew SSB, Adams WJ. Anal sphincter advancement flap for low transsphincteric anal fistula. Dis Colon Rectum 2007; 50: 1090–3. 45. Amin SN, Tierney GM, Lund JN, Armitage NC. V-Y advancement flap for treatment of fistula-in-ano. Dis Colon Rectum 2003; 46: 540–3. 46. Zimmerman DD, Briel JW, Gosselink MP, Schouten WR. Anocutaneous advancement flap repair of transsphincteric fistulas. Dis Colon Rectum 2001; 44: 1474–80. 47. Cintron JR, Park JJ, Orsay CP et al. Repair of fistulas-in-ano using autologous fibrin tissue adhesive. Dis Colon Rectum 1999; 42: 607–13. 48. Park JJ, Cintron JR, Orsay CP et al. Repair of chronic anorectal fistulae using commercial fibrin sealant. Arch Surg 2000; 135: 166–9. 49. Cintron JR, Park JJ, Orsay CP et al. Repair of fistulas-in- ano using fibrin adhesive: long-term follow-up. Dis Colon Rectum 2000; 43: 944–9. 50. Lindsey I, Smilgin-Humphreys MM, Cunningham C et al. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis Colon Rectum 2002; 45: 1608–15. 51. Sentovich SM. Fibrin glue for all anal fistulas. J Gastrointest Surg 2001; 5: 158–61. 52. Buchanan GN, Bartram CI, Phillips RK. Efficacy of fibrin sealant in the management of complex anal fistula. Dis Colon Rectum 2003; 46: 1167–74. 53. Loungnarath R, Dietz DW, Mutch MG et al. Fibrin glue treatment of complex anal fistulas has low success rate. Dis Colon Rectum 2004; 47: 432–6. 54. Gisbertz SS, Sosef MN, Festen S, Gerhards MF. Treatment of fistulas in ano with fibrin glue. Dig Surg 2005; 22: 91–4. 55. Maralcan G, Baskonus I, Aybasti N, Gokalp A. The use of fibrin glue in the treatment of fistula-in-ano: a prospective study. Surg Today 2006; 36: 166–70. 56. Adams T, Yang J, Kondylis LA, Kondylis PD. Long-term out- look after successful fibrin glue ablation of cryptoglandular transsphincteric fistula-in-ano. Dis Colon Rectum 2008; 51: 1488–90. 57. Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Dis Colon Rectum 2006; 49: 1736–40. 58. van Koperen PJ, Wind J, Bemelman WA, Slors JF. Fibrin glue and transanal rectal advancement flap for high transsphincteric perianal fistulas: is there any advantage? Int J Colorectal Dis 2008; 23: 697–701. 59. Jain SK, Kaza RCM, Pahwa M, Bansal S. Role of cyanoacrylate in the management of low fistula in ano: a prospective study. Int J Colorectal Dis 2008; 23: 355–8. 60. Barillari P, Basso L, Larcinese A et al. Cyanoacrylate glue in the treatment of ano-rectal fistulas. Int J Colorectal Dis 2006; 21: 791–4. 61. Singer M, Cintron J, Nelson R et al. Treatment of fistulas-in- ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the internal fistula opening. Dis Colon Rectum 2005; 48: 799–808. 62. Gustafsson UM, Graf W. Randomized clinical trial of local gentamycin-collagen treatment in advancement flap repair for anal fistula. Br J Surg 2006; 93: 1202–7. 63. Zmora O, Neufeld D, Ziv Y et al. Prospective, multicenter evaluation of highly concentrated fibrin blue in the treatment of complex cryptogenic perianal fistulas. Dis Colon Rectum 2005; 48: 2167–72. 64. Franklin ME Jr, Gonzalez JJ Jr, Michaelson RP et al. Preliminary experience with new bioactive prosthetic material for repair of hernias in infected fields. Hernia 2002; 6: 171–4. 65. Franklin ME Jr, Gonzalez JJ Jr, Glass JL. Use of porcine small intestine submucosa as a prosthetic device for laparoscopic repair of hernias in contaminated fields: 2-year follow-up. Hernia 2004; 8: 186–9. 66. Franklin ME Jr, Trevino JM, Portillo G et al. The use of small intestinal submucosa as a prosthetic material for laparoscopic hernia repair in infected and potentially contaminated fields: long-term follow-up. Surg Endosc 2008; 22: 1941–6. 67. Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin glue in closure of anorectal fistulas. Dis Colon Rectum 2006; 49: 371–6. 68. Champagne BJ, O’Connor LM, Ferguson M et al. Efficacy of anal fistula plug in closure of cryptoglandular fistulas: long- term follow-up. Dis Colon Rectum 2006;4 9: 1817–21. 69. O’Connor L, Champagne BJ, Ferguson MA et al. Efficacy of anal fistula plug in closure of Crohn’s anorectal fistulas. Dis Colon Rectum 2006: 49: 1569–73. 70. Ellis CN. Bioprosthetic plugs for complex anal fistulas: an early experience. J Surg Educ 2007; 64: 36–40. 71. van Koperen PJ, D’Hoore A, Wolthuis AM et al. Anal fistula plug for closure of difficult anorectal fistula: a prospective study. Dis Colon Rectum 2007; 50: 2168–72. 72. Schwandner O, Stadler F, Dietl O et al. Initial experience on efficacy in closure of cryptoglandular and Crohn’s transsphincteric fistulas by the use of the anal fistula plug. Int J Colorectal Dis 2008; 23: 319–24. 73. Lawes DA, Efron JE, Abbas M et al. Early experience with the bioabsorbable anal fistula plug. World J Surg 2008; 32: 1157–9. 74. Christoforidis D, Etzioni DA, Goldberg SM et al. Treatment of complex anal fistulas with the collagen fistula plug. Dis Colon Rectum 2008; 51: 1482–7. 75. Thekkinkattil D, Botterill I, Ambrose S et al. Efficacy of the anal fistula plug in complex anorectal fistulae. Colorectal Dis 2008 Jul 15 [Epub ahead of print]. 9 improved outcomes in colon and rectal surgery 76. Garg P. To determine the efficacy of anal fistula plug in the treatment of high fistula-in-ano – an initial experience. Colorectal Dis 2008 Jul 15 [Epub ahead of print]. 77. Ky AJ, Sylla P, Steinhagen R et al. Collagen fistula plug for the treatment of anal fistulas. Dis Colon Rectum 2008; 51: 838–43. 78. The Surgisis® AFP™ anal fistula plug: report of a consensus conference. Colorectal Dis 2008; 10: 17–20. 79. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tantiphlachiva K. Total anal sphincter saving technique for fistula-in-ano: the ligation of intersphincteric fistula tract. J Med Assoc Thai 2007; 90: 581–6. 80. Vasilevsky CA, Gordon PH. The incidence of recurrent abscesses or fistula-in-ano following anorectal suppuration. Dis Colon Rectum 1984; 27: 126–30. 81. Abcarian H. Surgical management of recurrent anorectal abscess. Contemp Surg 1982; 21: 85–91. 82. Onaca N, Hirshberg A, Adar R. Early reoperation for perirectal abscess: a presentable complication. Dis Colon Rectum 2001; 44: 1469–73. 83. Sangwan YP, Rosen L, Riether RD et al. Is simple fistula-in- ano simple? Dis Colon Rectum 1994; 37: 885–9. 84. Sygut A, Zajdel R, Kedzia-Budziewska R et al. Late results of treatment of anal fistulas. Colorectal Dis 2007; 9: 151–8. 85. Bennet RC. A review of orthodox treatment for anal fistula. Proc R Soc Med 1962; 55: 756–7. 86. Hill JR. Fistulas and fistulous abscesses in the anorectal region: personal experience in management. Dis Colon Rectum 1967; 10: 421–34. 87. Lilius HG. Fistula-in-ano, an investigation of human foetal anal ducts and intramuscular glands and a clinical study of 150 patients. Acta Chir Scand 1968; 383(Suppl): 1–88. 88. Mazier WP. The treatment and care of anal fistulas: a study of 1000 patients. Dis Colon Rectum 1971; 14: 134–44. 89. Ani AN, Solanke TF. Anal fistula: A review of 82 cases. Dis Colon Rectum 1976; 19: 51–5. 90. Marks CG, Ritchie JK. Anal fistulas at St. Mark’s Hospital. Br J Surg 1977; 64: 84–91. 91. Ewerth S, Ahlberg J, Collste G, Holmstrom B. Fistula-in- ano: a six year follow-up study of 143 operated patients. Acta Chir Scand 1978; 482(suppl): 53–5. 92. Adams D, Kovalcik PJ. Fistula-in-ano. Surg Gynecol Obstet 1981; 153: 731–3. 93. Kuijpers JHC. Diagnosis and treatment of fistula-in-ano. Neth J Surg 1982; 34: 147–52. 94. Sainio P, Husa A. A prospective manometric study of the effect of anal fistula surgery on anorectal function. Acta Chir Scand 1985; 151: 279–88. 95. Vasilevsky CA, Gordon PH. Results of treatment of fistula-in- ano. Dis Colon Rectum 1985: 28: 225–31. 96. Fucini C. One stage treatment of anal abscesses and fistulas. A clinical appraisal on the basis of two different classificaions. Int J Colorectal Dis 1991; 6: 12–6. 97. Van Tets WF, Kuijpers HC. Continence disorders after anal fisulotomy. Dis Colon Rectum 1994; 37: 1194–7. 98. Garcia-Aguilar JC, Belmonte C, Wong WD, Goldberg SM, Madoff RD. Surgical treatment of fistula-in-ano. Factors associated with recurrence and incontinence. Dis Colon Rectum 1996; 39: 723–9. 99. McElwain JM, Maclean D, Alexander RM et al. Anorectal problems: experience with primary fistulotomy for anorectal abscess, a report of 1000 cases. Dis Colon Rectum 1975; 27: 593–4. 100. Seow-Choen F, Phillips RKS. Insights gained from the management of problematic anal fistulae at St. Mark’s Hospital, 1984–88. Br J Surg 1991; 78: 539–41. 101. Lunniss PJ, Sheffield JP, Talbot IC et al. Persistence of idiopathic anal fistula may be related to epithelialization. Br J Surg 1995; 82: 32–3. 102. Williams JG, Macleod CAH, Goldberg SM. Seton treatment of high anal fistulas. Br J Surg 1991; 78: 1159–61. 103. Ramanujam PS, Prasad ML, Abcarian H. The role of seton in fistulotomy of the anus. Surg Gynecol Obstet 1983; 157: 419–22. 104. Kuijpers HC. Use of the seton in the treatment of extrasphincteric anal fistula. Dis Colon Rectum 1984; 27: 109–10. 105. Culp CE. Use of penrose drains to treat certain anal fistulas: a primary operative seton. Mayo Clin Proc 1984; 59: 613–17. 106. Christensen A, Miles J, Christiansen J. Treatment of transsphincteric anal fistulas by the seton technique. Dis Colon Rectum 1986; 29: 454–5. 107. Held D, Khubchandani I, Sheets J et al. Management of anorectal horseshoe abscess and fistula. Dis Colon Rectum 1986; 29: 793–7. 108. Fasth SB, Nordgren S, Hulten L. Clinical course and management of suprasphincteric and extrasphincteric fistula-in-ano. Acta Chir Scand 1990; 156: 397–402. 109. Graf W, Pahlman L, Egerbald S. Functional results after seton treatment of high transsphincteric anal fistulas. Eur J Surg 1995; 161: 289–91. 110. van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG. Long-term outcome following mucosal advancement flap for high perianal fistulas and fistulotomy for low perianal fistulas: recurrent perianal fistulas: failure of treatment or recurrent patient disease? Int J Colorectal Dis 2006; 21: 784–90. 111. van Koperen PJ, Wind J, Bemelman WA et al. Long- term functional outcome and risk factors for recurrence after surgical treatment for low and high perianal fistulas of cryptoglandular origin. Dis Colon Rectum 2008; 51: 1475–81. 112. Mizrahi N, Wexner SD, Zmora O et al. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum 2002; 45: 1616–21. 113. Zimmerman DD, Delamarre JB, Gosselink MP et al. Smoking affects the outcome of transanal mucosal advancement flap repair of trans-sphincteric fistulas. Br J Surg 2003; 90: 351–4. 114. Zimmerman DD, Gosselink MP, Mitalas LE et al. Smoking impairs rectal mucosal bloodflow – a pilot study: possible implications for transanal advancement flap repair. Dis Colon Rectum 2005; 48: 1228–32. 115. Seow-Choen F, Nicholls RJ. Anal fistula. Br J Surg 1992; 79: 197–205. 9 surgery and nonoperative therapy of perirectal abscesses and anal fistulas 116. Mazier WP. The treatment and care of anal fistulas: a study of 1000 patients. Dis Colon Rectum 1971; 14: 134–44. 117. Rosa G, Lolli P, Piccinelli D et al. Fistula-in-ano: anatomo- clinical aspects, surgical therapy and results in 844 patients. Tech Coloproctol 2006; 10: 215–21. 118. Aguilar PS, Plasencia G, Hardy TJ et al. Mucosal advancement in the treatment of anal fistula. Dis Colon Rectum 1985; 28: 496–8. 119. Dixon M, Root J, Grant S, Stamos MJ. Endorectal flap advancement repair is an effective treatment for selected patients with anorectal fistulas. Am Surg 2004; 70: 925–7. 120. Toyonaga T, Matsushima M, Kiriu T et al. Factors affecting continence after fistulotomy for intersphincteric fistula-in- ano. Int J Colorectal Dis 2007; 22: 1071–5. 121. Uribe N, Millan M, Minguez M et al. Clinical and manometric results of endorectal advancement flaps for complex anal fistula. Int J Colorectal Dis 2007; 22: 259–64. 122. Kreis ME, Jehle EC, Ohlemann M et al. Functional results after transanal rectal advancement flap repair of transsphincteric fistula. Br J Surg 1998; 85: 240–2. 123. Chang SC, Lin LK. Change in anal continence after surgery for intersphincteral anal fistula: a functional and manometric study. Int J Colorectal Dis 2003; 18: 111–5. 124. Perez F, Arroyo A, Serrano P et al. Fistulotomy with primary sphincter reconstruction in the management of complex fistula-in-ano: prospective study of clinical and manometric results. J Am Coll Surg 2005; 200: 897–903. 125. Ky A, Sohn N, Weinstein MA, Korelitz BI. Carcinoma arising in anorectal fistulas of Crohn’s disease. Dis Colon Rectum 1998; 41: 992–6. 126. Lockhart-Mummery HE. Symposium. Crohn’s disease: anal lesions. Dis Colon Rectum 1975; 18: 200–2. 127. Alexander-Williams J, Buchmann P. Perianal Crohn’s disease. World J Surg 1980; 4: 203–8. 128. Joo JS, Weiss EG, Nogueras JJ, Wexner SD. Endorectal advancement flap in perianal Crohn’s disease. Am Surg 1998; 64: 147–50. 129. Huber P Jr, Kissack AS, Simonton ST. Necrotizing soft tissue infection from rectal abscess. Dis Colon Rectum 1983; 26: 507–11. 130. Bubrick MP, Hitchcock CR. Necrotizing anorectal and perineal infections. Surgery 1979; 86: 655–62. 131. Lauks SS. Fournier’s gangrene in anorectal surgery. Surg Clin North Am 1994; 74: 1339–52. 132. Kovalcik P, Jones J. Necrotizing perineal infections. Am Surg 1983; 49: 163–6. 133. Lichtenstein GR. Treatment of fistulizing Crohn’s disease. Gastroenterology 2000; 119: 1132–47. 134. Thornton M, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn’s disease. Dis Colon Rectum 2005; 48: 459–63. 135. Turunen U, Farkkila M, Seppala K. Long-term treatment of perianl or fistulous Crohn’s disease with Ciprofloxacin (suppl 148). Scand J Gastroenterol 1989; 24: 144. 136. Wolf J. Ciprofloxacin may be useful in Crohn’s disease. Gastroenterology 1990; 98: A212. 137. Bernstein LH, Frank MS, Brandt LJ, Riley SJ. Healing of perianal Crohn’s disease with metronidazole. Gastroenterology 1980; 79: 357–65. 138. Brandt L, Bernstein L, Boley S, Frank M. Metronidazole therapy for perianal Crohn’s disease: a follow-up study. Gastroenterology 1982; 83: 383–7. 139. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984; 79: 533–40. 140. Schneider MU, Laudage G, Guggenmoos-Holzman I, Riemann JF. Metronidazol in der behandlung des morbus Crohn. Dtsch Med Wochenschr 1985; 110: 1724–30. 141. Solomon M, McLeod R, O’Connor B et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gastroenterol 1993; 7: 571–3. 142. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med 1980; 302: 981–7. 143. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985; 30: 58–64. 144. O’Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology 1991; 101: 39–46. 145. Feegan BC, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. N Eng J Med 1995; 332: 292–7. 146. Stein RB, Hanaper SB. Medical therapy for infammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 297–321. 147. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Eng J Med 2004; 350: 876–85. 148. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9. 149. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003: 9: 98–103. 150. Topstad DR, Panaccione R, Heine JA et al. Combined seton placement, infliximab infusion, and maintenance immu- nosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003; 46: 577–83. 151. Talbot C, Sagar PM, Johnston MJ et al. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 2005; 7: 164–8. 152. Poritz LS, Rowe WA, Koltun WA. Remicade does not abol- ish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum 2002; 45: 771–5. 153. Gaertner WB, Decanini A, Mellgren A et al. Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis Colon Rectum 2007; 50: 1754–60. 154. Kraemer M, Kirschmeier A, Marth T. Perioperative adjuvant therapy with infliximab in complicated anal Crohn’s disease. Int J Colorectal Dis 2008; 23: 965–9. . print]. 9 improved outcomes in colon and rectal surgery 76. Garg P. To determine the efficacy of anal fistula plug in the treatment of high fistula -in- ano – an initial experience. Colorectal. associated with anorectal surgery in the face of severe inflammation (unclear anatomy, bleeding, risk of inadvertent sphincter injury), and necrotizing perineal soft tissue infection (Fournier’s. healed in 8 weeks. Incontinence was seen in 6% of patients postoperatively, and recurrence was seen in 7%. Carcinoma Associated with Fistula -In- Ano In rare instances, patients with long-standing

Định dạng
Số trang	10
Dung lượng	204,28 KB